ORYZON to present ORY-2001 preliminary top line Phase I clinical data at the 13th International Conference on Alzheimer’s and Parkinson’s Diseases in Vienna, Austria

BARCELONA, SPAIN and CAMBRIDGE MA.

• The company will present an oral presentation and a poster on March 31st 2017

Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that it will present preliminary top-line clinical results from the first-in-man clinical trial to assess safety, tolerability and pharmacokinetics of ORY-2001, a novel epigenetic drug for treatment of neurodegenerative diseases, at the 13th ADPD International Conference to be held in Vienna, Austria from March 29th to April 2nd.

 

Click here to see the full Press Release